Latest close
$55.90
As of Oct 16, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Avoro Capital Advisors | 8.31% | 11,355,555 | ADDED (+6.1%) |
| Deerfield Management | 1.18% | 1,389,055 | TRIMMED (-11.7%) |
| Baker Bros. Advisors | 0.81% | 1,992,783 | HELD |
| Edgewood Management | 0.02% | 25,000 | HELD |
| Polen Capital Management | <0.01% | 6,612 | NEW |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Exited this quarter: RTW Investments.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
| Institutions holding | 505 of 8,857 filers |
| Long-only filers among them | 498 |
| Change vs 2026 Q1 | +74 net · 480 entered · 406 exited |
| Shares reported, all filers | 119,163,036 |
| Reported value, all filers | $9.7B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $829.4M |
| Net income · FY2025 | $-1.6M |
| Total assets · FY2025 | $1.4B |
| Shares outstanding | 141,254,467 |
| Market cap (at latest close) | $7.9B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Jul 30, 2026.
| Shares short · Sep 15, 2026 | 9,272,290 |
| Share of shares outstanding | 6.56% |
| Days to cover | 5.15 |
Shares short at recent settlements — Jun 30, 2026: 8.4M · Jul 15, 2026: 9.6M · Jul 31, 2026: 9.7M · Aug 14, 2026: 9.2M · Aug 31, 2026: 9.4M · Sep 15, 2026: 9.3M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.
| Shares failed to deliver · Sep 15, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Sep 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jun 30, 2026: 239 · Jul 15, 2026: 0 · Jul 31, 2026: 671 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 2 insiders ($1.2M).
Source: SEC Form 4 filings, as of Oct 18, 2026. Open-market transactions only.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
This stock does not currently pass any tracked screen.
Also held by the tracked funds that hold ARWR: Celcuity Inc. (CELC) · Taysha Gene Therapies, Inc. (TSHA) · BOSTON SCIENTIFIC CORP (BSX) · REVOLUTION MEDICINES INC (RVMD) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · Sionna Therapeutics, Inc. (SION) · STRUCTURE THERAPEUTICS INC (GPCR) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX) · XENON PHARMACEUTICALS INC (XENE).
Filings audit: every filing lens on ARROWHEAD PHARMACEUTICALS, INC. (ARWR), scored — GetCoattail Research.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.